SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TTPH, Tetraphase Pharmaceuticals
TTPH 2.200-3.5%Jul 28 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (30)9/10/2016 10:22:41 AM
From: HardToFind1 Recommendation

Recommended By
scaram(o)uche

  Read Replies (1) of 80
 
By the way, I just listened to the 24 August conference call. The company stated their determination that the failure of the oral drug had to do with patients taking it too close to meals, a factor for drug efficacy the company was apparently not aware of at the time of the failed trial.

The next trial is still essentially a planned repeat of the first successful IV-only treatment of complicated intra-abdominal infections (cIAI) trial starting in Q4 of 2016.

After that will be a trial repeating the successful IV-only treatment of complicated urinary tract infections (cUTI).

And finally a repeat of the recent failed IV-to-oral trial for complicated urinary tract infections (cUTI) will be held at some time in the future, only this timed a modified protocol to improve oral dosing efficacy.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News